Cargando…

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

INTRODUCTION: Since sipuleucel-T approval in 2010, the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) now includes the androgen-receptor signaling pathway inhibitors (ASPIs) abiraterone acetate or enzalutamide. In 2013 and 2014, these oral agents were approved for us...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKay, Rana R., Hafron, Jason M., Ferro, Christine, Wilfehrt, Helen M., Fitch, Kate, Flanders, Scott C., Fabrizio, Michael D., Schweizer, Michael T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596004/ https://www.ncbi.nlm.nih.gov/pubmed/33029725 http://dx.doi.org/10.1007/s12325-020-01509-5

Ejemplares similares

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents
por: Hafron, Jason M., et al.
Publicado: (2022)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Immune Response to Sipuleucel-T in Prostate Cancer
por: Thara, Eddie, et al.
Publicado: (2012)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Impact of HMO Withdrawals on Vulnerable Medicare Beneficiaries
por: Schoenman, Julie A., et al.
Publicado: (2005)

Medication adherence behaviors of Medicare beneficiaries
por: Carr-Lopez, Sian M, et al.
Publicado: (2014)

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
por: Bitting, Rhonda L., et al.
Publicado: (2011)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
por: Gulley, James L., et al.
Publicado: (2015)

Trends in Medicare Payments for Beneficiaries With Aortic Stenosis
por: van Bakel, Pieter A. J., et al.
Publicado: (2022)

Utilization of Medicare services by beneficiaries having partial Medicare coverage
por: McCall, Nelda
Publicado: (1983)

Effect of Medicare Advantage Payments on Dually Eligible Medicare Beneficiaries
por: Atherly, Adam, et al.
Publicado: (2005)

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
por: Bartlett, Victoria L., et al.
Publicado: (2020)

Mental Health of Medicare Beneficiaries: 1995
por: Eppig, Franklin J., et al.
Publicado: (1997)

Participation in the Qualified Medicare Beneficiary Program
por: Neumann, Peter J., et al.
Publicado: (1995)

Trends of Breast Reconstruction in Medicare Beneficiaries
por: Vyas, Krishna S., et al.
Publicado: (2020)

Bariatric surgery outcomes in Medicare beneficiaries
por: Wirth, Keith, et al.
Publicado: (2020)

Prevalence of Chronic Conditions Among Medicare Part A Beneficiaries in 2008 and 2010: Are Medicare Beneficiaries Getting Sicker?
por: Erdem, Erkan
Publicado: (2014)

The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
por: Ng, Laura, et al.
Publicado: (2013)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
por: Caram, Megan E. V., et al.
Publicado: (2019)

Recurrent Bilateral Strokes in a Patient Treated With Sipuleucel-T for Prostate Cancer
por: Gill, Jashan, et al.
Publicado: (2021)

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
por: Sutherland, Sarah I. M., et al.
Publicado: (2021)

Estimating Medicare Advantage Lock-In Provisions Impact on Vulnerable Medicare Beneficiaries
por: Laschober, Mary
Publicado: (2005)

Regional Variation in Rates of Total Knee Arthroplasty Among Medicare Beneficiaries
por: Ward, Michael M., et al.
Publicado: (2020)

Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
por: Zhao, Yang, et al.
Publicado: (2008)

Prevalence of HIV in Medicare beneficiaries with lung cancer
por: Lee, Jeannette Y, et al.
Publicado: (2012)

MCBS Highlights: Dually Eligible Medicare Beneficiaries
por: Murray, Lauren A., et al.
Publicado: (1998)

MCBS Highlights: Beneficiary Knowledge of the Medicare Program
por: Murray, Lauren A., et al.
Publicado: (1998)

Case Management for High-Cost Medicare Beneficiaries
por: Schore, Jennifer L., et al.
Publicado: (1999)

Prescription Drug Coverage and Spending for Medicare Beneficiaries
por: Poisal, John A., et al.
Publicado: (1999)

MCBS Highlights: Health Expenditures for Medicare Beneficiaries
por: Murray, Lauren A., et al.
Publicado: (1999)

A Profile of the Medicare Current Beneficiary Survey
por: Adler, Gerald S.
Publicado: (1994)

Predictability of Prescription Drug Expenditures for Medicare Beneficiaries
por: Wrobel, Marian V., et al.
Publicado: (2003)

Use of specialty hospitals by Medicare beneficiaries, 1985
por: Helbing, Charles, et al.
Publicado: (1988)

Variations in the use of physician services by Medicare beneficiaries
por: Stano, Miron, et al.
Publicado: (1988)

Postoperative Staphylococcus aureus Infections in Medicare Beneficiaries
por: Razavi, Moaven, et al.
Publicado: (2014)

Sensory Loss and Delirium Among Medicare Beneficiaries
por: Morales, Emmanuel Garcia, et al.
Publicado: (2020)

Covid-19 and excess mortality in medicare beneficiaries
por: Greenwald, Scott D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_utltq2tl1g6fig9h0k32m8r6mf